Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasmodium Immunotherapy for Advanced Ovarian Cancer
NCT05924776Phase 3Not yet recruiting
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 3 trial of plasmodium vivax in ovarian cancer, sponsored by CAS Lamvac Biotech Co., Ltd.. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
plasmodium vivax
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05924776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924776.